Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance

Respiratory Care

Volumn 58, Issue 9, 2013, Pages 1489-1494

  Sibila, Oriol ^a,c   Laserna, Elena ^a,d   Mortensen, Eric M ^b   Anzueto, Antonio ^a,e   Restrepo, Marcos I ^a,f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d Hospital Comarcal de Mollet   (Spain)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^f Veterans Evidence Based Research Dissemination and Implementation Center (VERDICT)   (United States)

Author keywords

Drug resistance; Inhaled corticosteroids; Pneumonia; Severity of illness index

Indexed keywords

CORTICOSTEROID; NITROGEN; UREA;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS; BLOOD PRESSURE; BREATHING RATE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG USE; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; ICD-9; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TEACHING HOSPITAL;

DRUG RESISTANCE; INHALED CORTICOSTEROIDS; PNEUMONIA; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84883308642     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02191     Document Type: Article

References (32)

1. Global Initiative for Asthma (GINA). The global strategy for asthma management and prevention. Updated December 2011. http://www.ginasthma.org/GINA-Report%2C-Global-Strategy-for-Asthma- Management-and-Prevention. Accessed June 21, 2013.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). The global strategy for the diagnosis, management and prevention of COPD, 2011. http://www.goldcopd.org/Guidelines/guidelinesresources.html. Accessed June 21, 2013.
3. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance: United States, 1971- 2000. MMWR Surveill Summ 2002;51(6):1-16.
4. Calverley P, Pauwel R, Vestbo J, Jones P, Pride N, Gulsik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003;361(9356):449-456. Erratum in: Lancet 2003;361(9369): 1660.
5. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;(4):CD003794.
6. Calverley PMA, Anderson JA, Celli B; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-789.
7. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(2):144-149.
8. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177(1):19-26.
9. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176(2): 162-166.
10. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407-2416.
11. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169(3):219-229.
12. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in COPD: A critical review and update. Curr Opin Pulm Med 2010;16(2):118-122.
13. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia. Eur Respir J 2010;36(4):751-757.
14. Singanayaman A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38(1):36-41.
15. Chen D, Restrepo MI, Fine MJ, Pugh MJ, Anzueto A, Metersky ML et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011; 184(3):312-316.
16. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989;11(6):954-963.
17. Conesa D, Rello J, Vallés J, Mariscal D, Ferreres JC. Invasive aspergillosis: a life-threatening complication of short-term steroid treatment. Ann Pharmacother 1995;29(12):1235-1237.
18. Maskell NA, Waine DJ, Lindley A, Pepperell JC, Wakefield AE, Miller RF, Davies RJ. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 2003;58(7):594-597.
19. Falguera M, Carratala J, Ruiz-Gonzalez, Garcia-Vidal C, Gazquez I, Dorca J, et al. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 2009;14(1): 105-111.
20. Sousa D, Justo I, Dominguez A, Manzur A, Izquierdo C, Ruiz L, et al. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect 2013;19(2):187-192.
21. Niederman MS, Mandell LA, Anzueto A, Barlett JG, Campbell GD, Dean NC, et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001;163(7):1730-1754.
22. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18(3):268-281.
23. Fine MJ, Auble TE, Yealey DM, Hanusa BH, Weissfeld LA, Singer DE et al. A prediction rule to identify low-risk patients with community- acquired pneumonia. N Engl J Med 1997;336(4):243-250.
24. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community- acquired pneumonia: a validation study. Thorax 2000;55(3): 219-223.
25. Restrepo MI, Mortensen EM, Anzueto A. Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? Eur Respir J 2011;38(1):1-3.
26. Crim C, Calverley PMA, Anderson JA, Celli B, Fergusson GT, Jenkins C. Pneumonia risk in COPD patients receiving inhaled inhaled corticoesteroids alone or in combination: TORCH study result. Eur Respir J 2009;34(3):641-647.
27. Singanayagam A, Chalmers JD, Hill AT. Inhaled corticoesteroids and risk of pneumonia: evidence for and against the proposed association. QJM 2010;103:379-385.
28. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359(22): 2355-2365.
29. Martinez R, Reyes S, Menendez R. Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. Curr Opin Pulm Med 2008;14(3):219-227.
30. Liapikou A, Polverino E, Ewig S, Cilloniz C, Marcos MA, Mensa J, et al. Severity and outcomes of hospitalized community-acquired pneumonia in COPD patients. Eur Respir J 2012;39(4):855-861.
31. Marin A, Monso E, Garcia-Nunez M, Sauleda J, Nogjera A, Pons J, et al. Variability and effects of bronchial colonization in patients with moderate COPD. EurRespir J 2010;35(2):295-302.
32. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340:c2096.